Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler® and Aerolizer®

Respiration

Volumn 73, Issue 4, 2006, Pages 441-448

  Dubakiene, Ruta ^a   Nargela, Remigijus ^a   Sakalauskas, Raimundas ^b   Vahteristo, Mikko ^c   Silvasti, Matti ^c   Lähelmä, Satu ^c  

^a VILNIUS UNIVERSITY   (Lithuania)

^b KAUNAS UNIVERSITY OF MEDICINE HOSPITAL   (Lithuania)

^c ORION CORPORATION   (Finland)

Author keywords

Asthma; Foradil Aerolizer ; Formoterol Easyhaler ; Multidose powder inhaler

Indexed keywords

FORMOTEROL FUMARATE; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BLOOD PRESSURE MEASUREMENT; BRONCHODILATATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MUSCLE CRAMP; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SINGLE DRUG DOSE; SPIROMETRY; STATISTICAL SIGNIFICANCE; TACHYCARDIA; TREMOR; VITAL SIGN;

ADULT; AGED; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; EQUIPMENT DESIGN; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; HUMANS; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PLACEBOS;

EID: 33745213198     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088896     Document Type: Article

References (31)

1. Bartow RA, Brogden RN: Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998;55:303-322.
2. Global Strategy for Asthma Management and Prevention: Global Initiative for Asthma (GINA) Workshop Report. NIH Publ No 02-3659. Issued January, 1995 (updated 2004). Available from URL:http://www.ginasthma.com.
3. European Commission: Communication from the Commission to the Council and the European Parliament: Strategy for the phaseout of CFCs in metered-dose inhalers. Offic J Eur Communities 1998;20:C355/2-C355/30.
4. Crompton GK: Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl 1982;119:101-104.
5. Montreal Protocol: Montreal Protocol on substances that deplete the ozone layer. 1998;adjusted/amended in Beijing 1999. Available from URL http://www.unep.org/ozone/Montreal-Protocol/Montreal-Protocol2000.shtml.
6. Ullman A, Löfdahl C-G, Melander B, Svedmyr N: Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study. Allergy 1996;51:745-748.
7. Lötvall J, Mellén A, Arvidsson P, Palmqvist M, Radielovic P, Kottakis J, Pfister P: Similar bronchodilation with formoterol delivered by aerolizer or turbuhaler. Can Respir J 1999;6:412-416.
8. Vidgren M, Silvasti M, Korhonen P, Kinkelin A, Frischer B, Stern K: Clinical equivalence of a novel multiple dose powder inhaler versus a conventional metered dose inhaler on bronchodilating effects of salbutamol. Arzneimittelforschung 1995;45:44-47.
9. Malmström K, Sorva R, Silvasti M: Application and efficacy of the multi-dose powder inhaler, Easyhaler®, in children with asthma. Pediatr Allergy Immunol 1999;10:66-70.
10. Koskela T, Hedman J, Ekroos H, et al: Equivalence of two steroid-containing inhalers: Easyhaler multidose powder inhaler compared with conventional aerosol with large-volume spacer. Respiration 2000;67:194-202.
11. Schweisfurth H, Malinen A, Koskela T, Toivanen P, Ranki-Pesonen M: Comparison of two budesonide powder inhalers, Easyhaler® and Turbuhaler®, in steroid-naïve asthmatic patients. Respir Med 2002;96:599-606.
12. Vanto T, Hämäläinen KM, Vahteristo M, Wille S, Njå F, Hyldebrandt N: Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. J Aerosol Med 2004;17:15-24.
13. Viljanen AA, Halttunen PK, Kreus K-E, Viljanen BC: Spirometric studies in non-smoking, healthy adults. Scand J Clin Lab Invest Suppl 1982;159:5-20.
14. Quebe-Fehling E, Brambilla R, Bromly CL, Fishwick K, Walters EH, Hendick DJ: The duration of action of inhaled formoterol dry powder. Br J Clin Pract 1996;50:446-449.
15. Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R: Onset and duration of action of single doses of formoterol inhaled via Turbuhaler®. Respir Med 1998;92:1017-1021.
16. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J: Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997;10:2484-2489.
17. Comment in Eur Respir J 1997;10:2441-2442.
18. van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV: Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996;9:1684-1688.
19. Wolfe J, Rooklin A, Grady J, et al: Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. J Allergy Clin Immunol 2000;105:1153-1161.
20. Nayak AS, Banov C, Corren J, et al: Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000;84:417-424.
21. Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL: What are minimal important changes for asthma measures in a clinical trial? Eur Respir J 1999;14:23-27.
22. Faulds D, Hollingshead LM, Goa KL: Formoterol: A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991;42:115-137.
23. Maesen FP, Costongs R, Smeets SJ, Zweers PG, Goedhart DM: Formoterol as dry powder inhalation: a dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 1992;101:1376-1381.
24. Anderson GP, Linden A, Rabe KF: Why are long-acting beta-adrenoreceptor agonists long-acting? Eur Respir J 1994;7:569-578.
25. Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lötvall J: Onset of bronchodilation of budesonide/formoterol vs. sameterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001;14:29-34.
26. Arvidsson P, Larsson S, Löfdahl CG, Melander B, Svedmyr N, Wahlander L: Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991;4:1168-1173.
27. Midgren B, Melander B, Persson G: Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects. Chest 1992;101:1019-1022.
28. Dahl R, Creemers JP, Van Noord J, et al: Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. Respiration 2004;71:126-133.
29. Burgess C, Ayson M, Rajasingham S, Crane J, Della Cioppa G, Till MD: The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol 1998;54:141-147.
30. Steffensen I, Faurschou P, Riska H, Rostrup J, Wegener T: Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease: a 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy 1995;50:657-663.
31. Molimard M, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G: A randomised, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 μg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients. Respiration 2005;72(suppl 1):28-34.